| Literature DB >> 35740118 |
Sada M Boyd1, Kristen L Rhinehardt2, Akamu J Ewunkem3, Scott H Harrison4, Misty D Thomas4, Joseph L Graves4.
Abstract
The rise in antimicrobial resistant bacteria have prompted the need for antibiotic alternatives. To address this problem, significant attention has been given to the antimicrobial use and novel applications of copper. As novel applications of antimicrobial copper increase, it is important to investigate how bacteria may adapt to copper over time. Here, we used experimental evolution with re-sequencing (EER-seq) and RNA-sequencing to study the evolution of copper resistance in Escherichia coli. Subsequently, we tested whether copper resistance led to rifampicin, chloramphenicol, bacitracin, and/or sulfonamide resistance. Our results demonstrate that E. coli is capable of rapidly evolving resistance to CuSO4 after 37 days of selection. We also identified multiple de novo mutations and differential gene expression patterns associated with copper, most notably those mutations identified in the cpx gene. Furthermore, we found that the copper resistant bacteria had decreased sensitivity when compared to the ancestors in the presence of chloramphenicol, bacitracin, and sulfonamide. Our data suggest that the selection of copper resistance may inhibit growth in the antimicrobials tested, resulting in evolutionary trade-offs. The results of our study may have important implications as we consider the antimicrobial use of copper and how bacteria may respond to increased use over time.Entities:
Keywords: Escherichia coli; antibiotics; copper; experimental evolution; genomics
Year: 2022 PMID: 35740118 PMCID: PMC9219993 DOI: 10.3390/antibiotics11060711
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1The mean and standard error (SE) of 24 h growth for Cu-selected, control, and ancestor populations in increasing concentrations of CuSO4 are shown. Cu-selected replicate populations demonstrated superior growth in CuSO4 concentrations of 8 mg/L to 62 mg/L when compared to the control and ancestor populations.
General linear model (GLM) results for phenotypic assays comparison for each population (Cu-selected, control, and ancestor) in each tested antimicrobial. The general linear model is an analysis of variance to determine the effect of the population (Cu-selected, control, and ancestral), the concentration (range tested for each antimicrobial), and their interaction. The GLM computes an F-statistic and the probability of achieving that F-statistic by chance (p value). NS means not significant.
| Antimicrobial | Concentration Effect | Population Effect | Interaction |
|---|---|---|---|
| Cu-selected > Controls | |||
| Copper (CuSO4) | F = 7.2 | F = 20.2 | NS |
| Chloramphenicol | NS | NS | NS |
| Sulfonamide | F = 16.5 | NS | NS |
| Cu-selected > Ancestor | |||
| Copper (CuSO4) | F = 6.96 | F = 20.5 | NS |
| Rifampicin | NS | F = 21 | NS |
| Controls > Ancestors | |||
| Copper (CuSO4) | F = 5.52 | NS | NS |
| Rifampicin | NS | F = 54 | F = 3 |
| Controls > Cu-selected | |||
| Chloramphenicol | F = 23.5 | 19.57 | NS |
| Bacitracin | F = 21.6 | NS | F = 2.14 |
| Magnesium | NS | NS | NS |
| Ancestor > Control | |||
| Chloramphenicol | F = 4.1 | 3.23 | NS |
| Bacitracin | F = 9.56 | NS | NS |
| Sulfonamide | F = 23.5 | F = 19 | NS |
| Ancestor > Cu-selected | |||
| Bacitracin | F = 17 | F = 13 | NS |
| Rifampicin | F = 16 | F = 9.1 | F = 5 |
| Chloramphenicol | F = 4 | NS | F = 3 |
| Sulfonamide | F = 17.4 | F = 8.5 | NS |
Figure 2The mean and SE of 24 h growth for Cu-selected, control, and ancestor populations in increasing concentrations of MgSO4 are shown. There is no significant difference between the Cu-selected replicates populations when compared to the control and ancestor populations.
Whole-genome resequencing results for the ancestors. Variant color coding: brown, hard-selective sweep/fixation; green, hard selection, major variant; blue, minor variant.
| Gene Name | Mutations | Ancestral Populations | Gene Description | ||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |||
| [crl] | Δ776 bp | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | [crl] |
| Δ1199 bp | 0.00 | 1.000 | 0.00 | 0.00 | 0.00 | UPF0056 family inner membrane protein/oligopeptide transporter subunit | |
|
| Δ776 bp | 1.000 | 1.000 | 1.000 | 0.00 | 1.000 | insB1, insA |
| IS5(+) + 4 bp | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | IS1 repressor TnpA/universal stress protein | |
|
| Δ2 bp | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | pseudogene, galactitol-specific enzyme IIC component of PTS transport; transport of small molecules: carbohydrates, organic acids, alcohols; PTS system galactitol-specific enzyme IIC |
| [rph]–[rph] | Δ82 bp | 0.442 | 0.00 | 0.104 | 0.912 | 0.00 | [rph], [rph] |
| C → T | 0.081 | 0.098 | 0.00 | 0.089 | 0.00 | glutamate/aspartate:proton symporter/Sel1 family TPR-like repeat protein | |
| A → G | 0.00 | 0.198 | 0.00 | 0.00 | 0.292 | “ | |
| A → C | 0.00 | 0.158 | 0.00 | 0.00 | 0.283 | “ | |
| T → C | 0.238 | 0.180 | 0.310 | 0.281 | 0.265 | “ | |
| C → T | 0.00 | 0.439 | 0.00 | 0.00 | 0.00 | “ | |
| +G | 0.00 | 0.00 | 0.00 | 0.836 | pseudogene, DNA-binding transcriptional repressor; regulator; energy metabolism, carbon: anaerobic respiration; repressor of the glp operon/pseudogene, DNA-binding transcriptional repressor; regulator; energy metabolism, carbon: anaerobic respiration; repressor of the glp operon | ||
| gltP/yjcO | +CG | 0.00 | 0.00 | 0.00 | 0.113 | 0.00 | maltose transporter subunit |
“ indicates that the gene definition is the same as above.
Whole-genome resequencing results after 37 days of selection to CuSO4. Variant Color coding: brown, hard-selective sweep/fixation; green, hard selection, major variant; blue, minor variant.
| Cu-Selected Replicate Populations after 37 Days of Selection to CuSO4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Name | Mutations | Cu1 | Cu2 | Cu3 | Cu4 | Cu5 | Cu6 | Cu8 | Cu9 | Cu10 | Gene Descriptions *Breseq and Uniprot |
|
| K194T (AAA → ACA) | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | sensory histidine kinase in two-component regulatory system with CpxR |
|
| K121R (AAA → AGA) | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | “ |
|
| V94A (GTG → GCG) | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | “ |
|
| R93H (CGC → CAC) | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | “ |
|
| K188Q (AAA → CAA) | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | “ |
|
| L178R (CTG → CGG) | 0.00 | 0.00 | 0.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | sensory histidine kinase in two-component regulatory system with CpxR |
|
| A78V (GCG → GTG) | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | “ |
|
| L20R (CTG → CGG) | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | response regulator in two-component regulatory system with CpxA |
|
| D104N (GAT → AAT) | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | “ |
|
| F62L (TTT → CTT) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.934 | 0.00 | 0.00 | inhibitor of the cpx response; periplasmic adaptor protein |
|
| Q128* (CAG → TAG) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.87 | “ |
|
| coding (228/2676 nt) | 0.00 | 0.00 | 0.00 | 0.00 | 0.385 | 0.00 | 0.00 | 0.00 | 0.00 | fused acetaldehyde-CoA dehydrogenase/iron-dependent alcohol dehydrogenase/pyruvate-formate lyase deactivase |
|
| coding (143-147/2676 nt) | 0.00 | 0.00 | 0.736 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | fused acetaldehyde-CoA dehydrogenase/iron-dependent alcohol dehydrogenase/pyruvate-formate lyase deactivase |
|
| V130I (GTT → ATT) | 0.00 | 0.00 | 0.00 | 0.00 | 0.392 | 0.00 | 0.00 | 0.00 | 0.00 | “ |
|
| coding (229/2676 nt) | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 | transcription termination factor |
|
| Q128* (CAG → TAG) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | transcription termination factor |
|
| Q128* (CAG → TAG) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.81 | 0.00 | transcription termination factor |
|
| H600Q (CAC → CAG) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.00 | 0.00 | 0.00 | RNA polymerase, sigma 70 (sigma D) factor |
|
| R109C (CGC → TGC) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | “ |
|
| P215L (CCA → CTA) | 0.00 | 0.00 | 0.674 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Inner membrane ABC transporter ATP-binding protein |
|
| Δ1 bp | 0.00 | 0.00 | 0.653 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | DNA-binding protein |
|
| coding (313-316/894 nt) | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | uncharacterized HTH-type transcriptional regulator |
| A262E (GCG → GAG) | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | family protein/long-chain fatty acid outer membrane transporter | |
“ means same gene definitions as above.
Whole-genome resequencing results for the controls. Variant color coding: brown, hard-selective sweep/fixation; green, hard selection, major variant; blue, minor variant.
| Gene Name | Mutations | Control Replicate Populations | Gene Description | ||||
|---|---|---|---|---|---|---|---|
| C1 | C2 | C3 | C4 | C5 | |||
|
| R191C (CGT → TGT) | 0.00 | 0.318 | 0.00 | 0.00 | 0.00 | RNA polymerase, alpha subunit |
|
| S712F (TCC → TTC) | 0.00 | 0.220 | 0.00 | 0.00 | 0.00 | RNA polymerase, beta subunit |
|
| R12H (CGT → CAT) | 0.00 | 0.00 | 0.462 | 0.00 | 0.00 | putative multidrug transporter subunit of ABC superfamily, membrane component/ATP-binding component |
|
| N762H (AAC → CAC) | 0.00 | 0.00 | 0.00 | 0.843 | 0.00 | RNA polymerase, beta prime subunit |
|
| coding (416–421/921 nt) | 0.00 | 0.252 | 0.00 | 0.00 | 0.00 | oligopeptide transporter subunit |
|
| coding (361/909 nt) | 0.00 | 0.565 | 0.00 | 0.00 | 0.00 | “ |
|
| Q128* (CAG → TAG) | 0.00 | 0.00 | 0.00 | 0.883 | 0.00 | “ |
|
| coding (361/909 nt) | 0.00 | 0.00 | 0.00 | 0.00 | 0.468 | “ |
|
| coding (416-421/921 nt) | 0.00 | 0.00 | 0.00 | 0.00 | 0.337 | “ |
|
| W254* (TGG → TGA) | 0.00 | 0.00 | 0.00 | 0.00 | 0.144 | “ |
|
| V259D (GTT → GAT) | 0.00 | 0.439 | 0.00 | 0.00 | 0.00 | mal regulon transcriptional activator |
|
| L431R (CTG → CGG) | 0.00 | 0.00 | 0.00 | 0.836 | 0.00 | “ |
|
| W155* (TGG → TAG) | 0.00 | 0.00 | 0.00 | 0.113 | 0.00 | maltose transporter subunit |
|
| E47G (GAG → GGG) | 0.113 | 0.00 | 0.00 | 0.00 | 0.00 | putative DNA-binding transcriptional regulator |
|
| E47G (GAG → GGG) | 0.00 | 0.0 | 0.00 | 0.153 | 0.00 | “ |
|
| E526G (GAG → GGG) | 0.097 | 0.00 | 0.00 | 0.00 | 0.00 | carbamoyl phosphate phosphatase and maturation protein for [NiFe] hydrogenases |
|
| L20L (CTG → CTA) | 0.00 | 0.091 | 0.00 | 0.00 | 0.00 | lipopolysaccharide core biosynthesis protein |
|
| S22P (TCA → CCA) | 0.00 | 0.168 | 0.00 | 0.00 | 0.00 | essential cell division protein |
|
| E69G (GAG → GGG) | 0.00 | 0.00 | 0.137 | 0.00 | 0.00 | acid-inducible Kdo/WaaP family putative kinase |
|
| H65P (CAC → CCC) | 0.00 | 0.00 | 1.000 | 0.00 | 0.00 | F1 sector of membrane-bound ATP synthase, gamma subunit |
|
| G85G (GGA → GGG) | 0.00 | 0.00 | 0.00 | 0.180 | 0.00 | |
|
| D104N (GAT → AAT) | 0.00 | 0.00 | 0.00 | 0.868 | 0.00 | nucleoside triphosphate pyrophosphohydrolase, marked preference for dGTP |
| coding (229/2676 nt) | 0.00 | 0.00 | 0.00 | 0.847 | 0.00 | BamABCDE complex OM biogenesis outer membrane pore-forming assembly factor/periplasmic chaperone | |
|
| coding (228/2676 nt) | 0.00 | 0.00 | 0.00 | 0.132 | 0.00 | CP4-6 prophage; putative xylosidase/arabinosidase |
|
| V130I (GTT → ATT) | 0.00 | 0.00 | 0.00 | 0.110 | 0.00 | transcription antitermination protein |
|
| H600Q (CAC → CAG) | 0.00 | 0.00 | 0.00 | 0.823 | 0.00 | nitroreductase A, NADPH-dependent, FMN-dependent |
|
| F62L (TTT → CTT) | 0.00 | 0.00 | 0.00 | 0.150 | 0.00 | transcriptional activator for tynA and feaB |
|
| Q128* (CAG → TAG) | 0.00 | 0.00 | 0.00 | 0.111 | 0.00 | 3-hydroxyadipyl-CoA dehydrogenase, NAD+-dependent |
|
| Q128* (CAG → TAG) | 0.00 | 0.00 | 0.00 | 0.214 | 0.00 | methionine |
|
| pseudogene (381/475 nt) | 0.00 | 0.00 | 0.00 | 0.922 | 0.00 | pseudogene (381/475 nt) |
|
| K283N (AAA → AAC) | 0.00 | 0.000 | 0.00 | 0.854 | 0.00 | putative PTS enzyme, Hpr component/enzyme I component/enzyme IIA component |
| intergenic (+18/−366) | 0.00 | 0.00 | 0.00 | 0.860 | 0.00 | cysteine synthase A, | |
|
| F62L (TTT → CTT) | 0.00 | 0.00 | 0.00 | 0.150 | 0.00 | transcriptional activator for tynA and feaB |
|
| Q128* (CAG → TAG) | 0.00 | 0.00 | 0.00 | 0.111 | 0.00 | 3-hydroxyadipyl-CoA dehydrogenase, NAD+-dependent |
|
| T204P (ACT → CCT) | 0.00 | 0.00 | 0.00 | 0.185 | 0.00 | aminoglycoside/multidrug efflux system |
|
| E368D (GAA → GAC) | 0.00 | 0.00 | 0.00 | 0.876 | 0.00 | fused glutathionylspermidine amidase/glutathionylspermidine synthetase |
|
| I54S (ATT → AGT) | 0.00 | 0.00 | 0.00 | 0.921 | 0.00 | hydrogenase 2, small subunit |
| ygjV | G87D (GGC → GAC) | 0.00 | 0.00 | 0.00 | 0.165 | 0.00 | Imp-YgjV family inner membrane protein |
|
| F10V (TTT → GTT) | 0.00 | 0.00 | 0.00 | 0.857 | 0.00 | targeting factor for csrBC sRNA degradation |
|
| V63V (GTT → GTG) | 0.00 | 0.00 | 0.00 | 0.861 | 0.00 | 50S ribosomal subunit protein L23 |
|
| A45E (GCA → GAA) | 0.00 | 0.00 | 0.00 | 0.091 | 0.00 | YibB family protein, function unknown |
|
| L61R (CTG → CGG) | 0.00 | 0.00 | 0.00 | 0.124 | 0.00 | putative DNA-binding transcriptional regulator; KpLE2 phage-like element |
|
| G282G (GGT → GGG) | 0.00 | 0.00 | 0.00 | 0.798 | 0.00 | 6-phosphofructokinase I |
| intergenic (+229/−122) | 0.00 | 0.00 | 0.00 | 0.127 | 0.00 | pseudogene, | |
“ indicates that the gene definition is the same as above.
Functional annotation clustering for upregulated and downregulated genes. There was one significant cluster for upregulated genes, which was associated with ABC binding. There were three significant clusters associated with bacterial flagellum, iron transport, and cell division among downregulated genes.
| Functional Annotation Cluster | Enrichment Score a | Gene Count | |
|---|---|---|---|
| Upregulated | Cluster 1 | 1.34 | 17 |
| Downregulated | Cluster 1 | 3.51 | 14 |
| Cluster 2 | 1.37 | 11 | |
| Cluster 3 | 1.07 | 6 |
a. Enrichment score threshold was set to 1 and gene count ≥ 4.
Figure 3Hierarchical clustering of upregulated genes. Shown here are genes that were upregulated in at least four Cu-selected replicates with a 2-fold-change or above that were not expressed in the control populations. The rows and columns of the heatmaps are clustered based on similar observations.
Figure 4Hierarchical clustering of downregulated genes. Shown here are genes that were downregulated in at least four Cu-selected replicates with a 0.5-fold-change or below that were not expressed in the control populations. The rows and columns of the heatmaps are clustered based on similar observations.
Figure 5The mean and SE of 24 h growth for Cu-selected, control, and ancestor populations in increasing concentrations of the antibiotics chloramphenicol, bacitracin, rifampicin, and sulfonamide. The ancestor populations grew better than the Cu-selected and control populations in the presence of chloramphenicol (4–16 mg/L) (A); the control populations showed better growth than the ancestor and Cu-selected populations in rifampicin (B). In acitracin, the ancestor and control populations grew better than the Cu-selected populations at 4–125 mg/L (C). The ancestor populations also showed superior growth when compared to the Cu-selected populations in the presence of sulfonamide (16–62 mg/L) (D).
Figure 6Mapping Cpx mutations onto three-dimensional protein structures. (A) CpxR mutations were mapped onto the solved structure of the receiver domain (PDB 4UHK); phosphorylated aspartate and magnesium ion are colored in magenta. All detected mutations were mapped, including D104N (blue) and L20R (red). (B) Q128* was the only detected CpxP mutation and was mapped onto the dimeric structure (PDB 3QZ3). Q128 resides in one of the two conserved LTXXQ motifs in each monomer (green), and this premature stop codon would halt translation of the final helix (red). (C) Currently, a crystal structure is only available for the cytoplasmic ATPase domain of CpxA (PDB 5LFK) and, therefore, only two mutations P215L (red and only structured in one monomer) and A262E (blue, present in both monomers) could be mapped.
ReadsPerGene.out.tab File Differential Expression Analysis.
| Column 1 | Gene ID |
| Column 2 | Counts for unstranded RNA-seq |
| Column 3 | Counts for the 1st read strand aligned with RNA |
| Column 4 | Counts for the 2nd read strand aligned with RNA |
Description of pairwise comparison groups. DESeq2 was used to calculate the fold change differences for four pairwise comparisons. Group 1 compares the Cu-selected populations in CuSO4 to the Controls in CuSO4. Group 2 compares the Cu-selected populations in CuSO4 to the Cu-selected populations in DMB only. Group 3 compares the Controls in CuSO4 to the Controls in DMB only. Group 4 identified uniquely expressed genes in Cu-selected populations in CuSO4 that were not expressed in the controls in CuSO4 when compared to both replicate populations in DMB. Essentially, Group 4 is the result of comparing Groups 1 and 3 and was used for all the further analysis in this study.
| Groups | Fold-Change Comparison |
|---|---|
| Group 1 | Cu-selected in CuSO4 compared to Controls in CuSO4 |
| Group 2 | Cu-selected in CuSO4 compared to Cu-selected in DMB only |
| Group 3 | Controls in CuSO4 compared to controls in DMB only |
| Group 4 | Uniquely expressed genes in Cu-selected in CuSO4 not expressed in the controls in CuSO4 (compares Groups 1 and 3) |